Since the borderline changes suspicious for acute T cell–mediated rejection (BL) category was broadened, there has been a debate regarding the right threshold for tubulitis and interstitial inflammation scores.
We studied a first cohort of 111 patients with BL found on an indication biopsy between 2006 and 2016 and compared those with scores of t1i0 (BLt1i0) to those with higher scores (BL≥t1i1). A second cohort of 56 patients with BL was used for external validation. We used a composite endpoint of death-censored graft failure or doubling of the serum creatinine level postbiopsy.
In the first cohort, 68% (75/111) of the BL cases fell in the BLt1i0 group. At 5 years, the occurrence of the composite endpoint was 5% and 14% for BLt1i0 and BL≥t1i1, respectively. In contrast, the endpoint occurred in 5% of nonrejectors and 21% of patients with T cell–mediated rejection. In the validation cohort, 8% versus 36% of BLt1i0 and BL≥t1i1 reached the endpoint, respectively. Multivariable Cox modeling revealed that BLt1i0 patients had a prognosis similar to that of nonrejectors (adjusted hazard ratio, 0.6; 95% confidence interval, 0.1-2.2; P = 0.40) but better than that of patients with BL≥t1i1 (hazard ratio, 3.8; 95% confidence interval, 1.3-11.5; P = 0.02). Sensitivity analyses restricted to death-censored graft loss or using time posttransplant as the time of reference provided similar results.
In summary, patients with BLt1i0 have a different prognosis to that of BL≥t1i1 patients, which brings into question the current diagnostic thresholds.
In order to evaluate the most appropriate threshold of t and i in the borderline changes suspicious for T cell acute rejection Banff category, the authors compare various outcomes according the severity of histological lesions on indication biopsies. Overall, patients with t1i0 and no rejection share the same prognosis while those with ≥t1i1 have a worse prognosis.
1 Transplantation Unit, Renal Division, Department of Medicine, University Health Center of Quebec, Faculty of Medicine, Laval University, Québec, QC, Canada.
2 Department of Pathology, University Health Center of Quebec, Faculty of Medicine, Laval University, Québec, QC, Canada.
3 Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY.
4 Department of Medicine, Division of Nephrology, Columbia University Medical Center, New York, NY.
Received 12 January 2018. Revision received 9 May 2018.
Accepted 3 June 2018.
M.M.R. and F.B.-B. contributed equally to this work and should be regarded as co-first authors.
Ibrahim Batal MD and Sacha A. De Serres MD SM These authors supervised this work and should be regarded as cosenior authors.
The authors declare no conflicts of interest.
This work received support from Canadian Institutes of Health Research through Operating Grant 201309 PCL-134068 and Canada Foundation for Innovation Grant 31981. S.A.D.S. was supported by a scholarship from the Fonds de Recherche Québec Santé (FRQS) Grant 24676. S.B. is the recipient of a scholarship from CIHR and FRQS.
M.M., F.B.B., and S.A.D.S. participated in research design, performance of the research, data analysis and writing of the article. O.D., S.B., E.L., J.R., D.S., S.A.H., and I.B. participated in data analysis and writing of the article. I.H., R.N., I.C., I.L., and J.L. participated in research design and in the writing of the article.
Correspondence: Sacha A. De Serres, MD SM FRCPC Transplantation Unit, Renal Division Department of Medicine, University Health Center of Quebec Faculty of Medicine, Laval University, 11 Côte du Palais Quebec, QC, Canada G1R 2J6. (email@example.com).
Supplemental digital content (SDC) is available for this article. Direct URL citations appear in the printed text, and links to the digital files are provided in the HTML text of this article on the journal’s Web site (www.transplantjournal.com).